Plain-English translation of NCT06947304 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing , a new medication designed to reduce fat accumulation in the liver for people with metabolic dysfunction-associated steatohepatitis (MASH). Researchers want to see how the medication affects liver fat levels and whether it is safe and well-tolerated. This trial will enroll about 8 patients over a 16-week period.
Fatty liver disease linked to metabolic problems—like obesity, diabetes, and high blood pressure—affects millions of people and can progress to serious liver damage. Current treatment options are limited, so researchers are testing this medication to see if it offers a new way to help reduce liver fat and prevent the condition from worsening.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will take 100 mg of the medication by mouth every day for 6 weeks. Your participation includes a 6-week screening period (with tests and scans to confirm you have fatty liver disease), the 6-week treatment phase, and a 4-week follow-up period after you stop taking the medication—totaling about 16 weeks. You will have regular clinic visits to check how you are doing and to measure changes in your liver fat using blood tests and imaging scans.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Corcept Therapeutics
Collaborators
University of Missouri-Columbia
Enrollment target
~8 participants
Started
August 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elizabeth Parks, PhD
Corcept Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.